MX345019B - Nuevo anticuerpo ctgf antihumano. - Google Patents

Nuevo anticuerpo ctgf antihumano.

Info

Publication number
MX345019B
MX345019B MX2014007681A MX2014007681A MX345019B MX 345019 B MX345019 B MX 345019B MX 2014007681 A MX2014007681 A MX 2014007681A MX 2014007681 A MX2014007681 A MX 2014007681A MX 345019 B MX345019 B MX 345019B
Authority
MX
Mexico
Prior art keywords
human ctgf
ctgf antibody
seq
amino acid
acid sequence
Prior art date
Application number
MX2014007681A
Other languages
English (en)
Other versions
MX2014007681A (es
Inventor
Iwasaki Shoji
Moriya Ryuichi
Yoshino Masayasu
Takakura Koji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2014007681A publication Critical patent/MX2014007681A/es
Publication of MX345019B publication Critical patent/MX345019B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo CTGF antihumano que tiene una actividad de unión superior y/o una actividad neutralizante superior en comparación con aquella de los anticuerpos CTGF antihumanos convencionales; y un medio para prevenir o tratar varias enfermedades en las que el CTGF humano está implicado en la formación de condiciones clínicas de los mismos, que incluye las enfermedades renales como la enfermedad renal crónica y la nefropatía diabética, al usar el anticuerpo CTGF antihumano mencionado. Un anticuerpo CTGF antihumano que contiene una región variable de cadena pesada que comprende la secuencia de aminoácidos representada por la SEC ID NO: 10 y una región variable de cadena ligera que comprende la secuencia de aminoácidos representada por SEC ID NO: 4.
MX2014007681A 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano. MX345019B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Publications (2)

Publication Number Publication Date
MX2014007681A MX2014007681A (es) 2014-11-25
MX345019B true MX345019B (es) 2017-01-11

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007681A MX345019B (es) 2011-12-22 2012-12-21 Nuevo anticuerpo ctgf antihumano.

Country Status (16)

Country Link
US (1) US9587015B2 (es)
EP (1) EP2796550B1 (es)
JP (1) JP6040943B2 (es)
KR (1) KR20140107507A (es)
CN (1) CN104011206B (es)
AR (1) AR089425A1 (es)
BR (1) BR112014015405A2 (es)
CA (1) CA2859627A1 (es)
EA (1) EA029290B1 (es)
ES (1) ES2665851T3 (es)
IN (1) IN2014CN04615A (es)
MX (1) MX345019B (es)
PL (1) PL2796550T3 (es)
PT (1) PT2796550T (es)
TW (1) TW201333034A (es)
WO (1) WO2013094723A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
EP3981787A4 (en) * 2019-06-04 2022-09-14 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODIES AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS USE
CN116391041A (zh) * 2020-12-03 2023-07-04 江苏恒瑞医药股份有限公司 一种含抗结缔组织生长因子抗体的药物组合物
EP4537841A1 (en) 2022-06-07 2025-04-16 Astellas Pharma, Inc. Pharmaceutical composition containing anti-integrin alpha-11 antibody for treatment or prevention of aging-related diseases
KR20250097820A (ko) 2022-10-31 2025-06-30 아스텔라스세이야쿠 가부시키가이샤 Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US6114143A (en) 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CN1660911A (zh) 1998-12-14 2005-08-31 迈阿密大学 结缔组织生长因子片段及其方法和用途
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
AR089425A1 (es) 2014-08-20
PL2796550T3 (pl) 2018-08-31
PT2796550T (pt) 2018-04-18
EP2796550B1 (en) 2018-02-28
EA201491240A1 (ru) 2014-11-28
EA029290B1 (ru) 2018-03-30
CA2859627A1 (en) 2013-06-27
KR20140107507A (ko) 2014-09-04
BR112014015405A2 (pt) 2017-06-13
US20140343258A1 (en) 2014-11-20
US9587015B2 (en) 2017-03-07
WO2013094723A1 (ja) 2013-06-27
CN104011206B (zh) 2017-03-08
MX2014007681A (es) 2014-11-25
JPWO2013094723A1 (ja) 2015-04-27
EP2796550A4 (en) 2015-08-19
CN104011206A (zh) 2014-08-27
EP2796550A1 (en) 2014-10-29
ES2665851T3 (es) 2018-04-27
TW201333034A (zh) 2013-08-16
JP6040943B2 (ja) 2016-12-07
IN2014CN04615A (es) 2015-09-18

Similar Documents

Publication Publication Date Title
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
NZ610734A (en) Human antibodies to the glucagon receptor
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
IN2014CN04615A (es)
WO2009048537A3 (en) Humanized antibody
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX351273B (es) Nuevo anticuerpo anti-ngf humano.
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
WO2013120012A3 (en) Cdim binding proteins and uses thereof
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
JP2014530215A5 (es)
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
NZ628943A (en) Human antibodies to clostridium difficile toxins
EA201491235A1 (ru) Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc
EP2548574A4 (en) NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST CD20
NZ603191A (en) Methods for the treatment of il-1b related conditions
MX347955B (es) Novedoso anticuerpo anti-receptor de il-23 humano.
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体

Legal Events

Date Code Title Description
FG Grant or registration